Structural heart disease devicemaker lands $250K in seed money

Micro Interventional Devices is taking aim at structural heart disease with the help of $250,000 in seed money from the Life Sciences Greenhouse of Central Pennsylvania.

The young Bethlehem, PA-based company's first offering is a minimally invasive device called Permaseal, which gives access and wound closure during structural heart repair procedures. What's cool is that the device moves with the beating heart while still keeping the edges of the wound closed. Further, it allows for wound healing without the use of sutures.

The company's offering allows the surgeon to remotely affix an implant to the apex of the heart, creating an access site on the myocardial surface of the organ. It is especially helpful during transcatheter aortic valve implantation, transcatheter mitral valve replacement, mitral valve repair and other heart repair procedures, according to the company.

MID's management is composed of folks with a vast amount of medical device experience. For example, President and CEO Michael Whitman previously held positions at Johnson and Johnson ($JNJ), Olympus, Synthes and Power Medical Interventions, which Covidien ($COV) bought in 2009. Other company executives' résumés include stints at Covidien and Medtronic ($MDT), among other companies.

- get the LSGPA release

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.